Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HGT-1111 in late infantile metachromatic leukodystrophy
NCT00681811Phase 2Terminated
- Sponsor
- Takeda
- Start
- Feb 2008
- Primary completion
- Oct 2010
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cebsulfase alfa in late-infantile metachromatic leukodystrophy (MLD) (2 arms), sponsored by Takeda. Primary endpoint: Days of Exposure to HGT-1111 at 139 weeks. Started Feb 2008; status: terminated.
02
Drugs
cebsulfase alfa
03
Conditions
late-infantile metachromatic leukodystrophy (MLD)
Beyond the preview
Go deeper on NCT00681811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681811.